Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial

The clinical benefit of eribulin versus capecitabine was evaluated using health-related quality of life (HRQoL) data from a phase 3 randomized trial in patients with pretreated advanced/metastatic breast cancer (ClinicalTrials.gov identifier: NCT00337103). The study population has been described pre...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Breast Cancer Res Treat
Hoofdauteurs: Cortes, Javier, Hudgens, Stacie, Twelves, Chris, Perez, Edith A., Awada, Ahmad, Yelle, Louise, McCutcheon, Susan, Kaufman, Peter A., Forsythe, Anna, Velikova, Galina
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer US 2015
Onderwerpen:
Clinical Trial
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4661183/
https://ncbi.nlm.nih.gov/pubmed/26567010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-015-3633-7
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items